Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jennifer McLaughlin

Physician Assistant Wasilla, AK Physician Assistant

NPI 1184237174 CMS profile 11270871

3122 E Meridian Park Loop, Wasilla, AK 99654

Open in the dashboard

General payments

$3,635

157 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer McLaughlin of Wasilla, AK is reported in the CMS Open Payments database as having received $3,635 across 157 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,050 45
2024 General $985 42
2023 General $1,024 44
2022 General $456 24
2021 General $121 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer McLaughlin
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jennifer McLaughlin were reported at $1,050. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jennifer McLaughlin Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $121 $132 $37–$438 $132
2022 $456 $155 $48–$522 $149
2023 $1,024 $167 $52–$557 $160
2024 $985 $178 $55–$600 $164
2025 $1,050 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $854 33 payments
  2. AbbVie, Inc. $676 30 payments
  3. Pfizer Inc. $398 19 payments
  4. ITI, Inc. $280 8 payments
  5. Amgen Inc. $214 5 payments
  6. GlaxoSmithKline, LLC. $184 10 payments
  7. Exact Sciences Corporation $139 7 payments
  8. Novo Nordisk Inc $137 8 payments
  9. Novartis Pharmaceuticals Corporation $120 5 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $81 4 payments
  11. Other $552 28 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,635 157 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $327 13 payments
  2. BREZTRI $302 14 payments
  3. AIRSUPRA $282 11 payments
  4. FARXIGA $278 9 payments
  5. UBRELVY $240 12 payments
  6. CAPLYTA $233 6 payments
  7. NURTEC ODT $219 12 payments
  8. EVENITY $183 3 payments
  9. XIFAXAN $163 8 payments
  10. Cologuard Collection Kit $139 7 payments
  11. Other $2,016 99 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

1,482

Median for Physician Assistant: 241

Drug cost

$199,593

Median for Physician Assistant: $4,110

Branded share of claims

24%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 45 $59,183
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 29 $35,952
Eliquis Apixaban Brand 21 $34,128
Jardiance Empagliflozin Brand 18 $21,240
Myrbetriq Mirabegron Brand 13 $15,859
Linzess Linaclotide Brand 14 $11,706
Albuterol Sulfate Hfa Albuterol Sulfate Brand 56 $2,402
Levothyroxine Sodium Generic 100 $1,490
Sertraline Hcl Generic 22 $1,292
Omeprazole Generic 72 $1,136

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$53,933

Of which drugs: $2,376

Medicare patients

325

Average age 71

Services billed

1,107

217 women, 108 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 61%
Arthritis 42%
Diabetes 26%
Ischemic heart disease 21%
Depression 16%
Atrial fibrillation 13%
Osteoporosis 13%
COPD 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 11 45 $39

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $198
$198 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $134
$134 — —
VRAYLAR
  • AbbVie, Inc. $104
$104 — —
NURTEC ODT
  • PFIZER INC. $101
$101 — —
UBRELVY
  • AbbVie, Inc. $51
$51 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

157 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Alaska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record